4.2 Article

Psychobiology of mindfulness

Journal

CNS SPECTRUMS
Volume 13, Issue 9, Pages 752-756

Publisher

CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1092852900013869

Keywords

-

Funding

  1. AstraZeneca
  2. Eli Lilly
  3. GlaxoSmithKline
  4. Lundbeck A/S
  5. Orion
  6. Pfizer
  7. Pharmacia
  8. Roche
  9. Servier
  10. Solvay
  11. Sumitomo
  12. Wyeth
  13. Medical Research Council of South Africa

Ask authors/readers for more resources

There is controversy about whether mindfulness-based approaches to psychotherapy represent a new wave of cognitive-behavioral therapy or a core process in all psychotherapies. One way of conceptualizing mindfulness is in terms of emotion regulation; mindfulness is a strategy aimed at opposing suppression and avoidance. Dispositional mindfulness has been associated with greater activation in prefrontal cortex and greater deactivation of amygdala during affect labeling. A number of rigorous studies of mindfulness-based cognitive therapy for depression have been positive. However, much remains to be discovered about the underlying mechanisms of and clinical indications for mindfulness-based approaches.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available